| Name | Title | Contact Details |
|---|
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company`s lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States. ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR.
Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing innovative therapeutics for cats and dogs.
Sunovion Pharmaceuticals Inc. leads the way to a healthier tomorrow by creating medicines for respiratory diseases and central nervous system disorders.
Westerner Park is a Red Deer, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
TherapeuticsMD is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.